Proteomics in bone research

References

• Rodan GA. Bone mass homeostasis and bisphosphonate action. Bone20, 1–4 (1997).
   PubMedGoogle Scholar
• Raisz LG, Rodan GA. Pathogenesis of osteoporosis. Endocrinol. Metab. Clin. North Am.32, 15–24 (2003).
   PubMed Web of Science ®Google Scholar
• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med.94, 646–650 (1993).
   PubMed Web of Science ®Google Scholar
• Melton LJ 3rd. How many women have osteoporosis now? J. Bone Miner. Res.10, 175–177 (1995).
   PubMed Web of Science ®Google Scholar
• Advisory Group on Osteoporosis. Report. Department of Health, London, UK (1994).
   Google Scholar
• Abbott TA 3rd, Lawrence BJ, Wallach S. Osteoporosis: the need for comprehensive treatment guidelines. Clin. Ther.18, 127–149 (1996).
   PubMed Web of Science ®Google Scholar
• Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science289, 1508–1514 (2000).
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev.23, 279–302 (2002).
   PubMed Web of Science ®Google Scholar
• Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. J. Clin. Endocrinol. Metab.90, 6323–6331 (2005).
   PubMed Web of Science ®Google Scholar
• Srivastava S, Weitzmann MN, Kimble RB et al. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J. Clin. Invest.102, 1850–1859 (1998).
   PubMedGoogle Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science289, 1504–1508 (2000).
   PubMed Web of Science ®Google Scholar
• Fatayerji D, Mawer EB, Eastell R. The role of insulin-like growth factor I in age-related changes in calcium homeostasis in men. J. Clin. Endocrinol. Metab.85, 4657–4662 (2000).
   PubMed Web of Science ®Google Scholar
• Seeman E. Invited review: pathogenesis of osteoporosis. J. Appl. Physiol.95, 2142–2151 (2003).
   PubMed Web of Science ®Google Scholar
• Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology140, 3552–3561 (1999).
   PubMed Web of Science ®Google Scholar
• Miura M, Tanaka K, Komatsu Y et al. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. Biochem. Biophys. Res. Commun.291, 987–994 (2002).
   PubMedGoogle Scholar
• Selye H. On the stimulation of new bone-formation with parathyroid extract and irradiated ergosterol. Endocrinology16, 547–558 (1932).
   Google Scholar
• Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest.102, 1627–1633 (1998).
   PubMed Web of Science ®Google Scholar
• Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med.338, 485–492 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher JE, Rogers MJ, Halasy JM et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl Acad. Sci. USA96, 133–138 (1999).
   PubMed Web of Science ®Google Scholar
• Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med.353, 99–102 (2005).
   PubMed Web of Science ®Google Scholar
• Siris ES, Roodman GD. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition). Favus MJ (Ed.). ASBMR Washington, WA, USA 320–330 (2006).
   Google Scholar
• Mills BG, Singer FR, Weiner LP, Suffin SC, Stabile E, Holst P. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget’s disease of bone. Clin. Orthop. Relat. Res.1(183), 303–311 (1984).
   Google Scholar
• Hughes AE, Ralston SH, Marken J et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet.24, 45–48 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas RJ, Guise TA, Yin JJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology140, 4451–4458 (1999).
   PubMed Web of Science ®Google Scholar
• Yin JJ, Selander K, Chirgwin JM et al. TGF-β a signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest.103, 197–206 (1999).
   PubMed Web of Science ®Google Scholar
• Romas E, Bakharevski O, Hards DK et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum.43, 821–826 (2000).
   PubMed Web of Science ®Google Scholar
• Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell89, 755–764 (1997).
   PubMed Web of Science ®Google Scholar
• Nakashima K, Zhou X, Kunkel G et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell108, 17–29 (2002).
   PubMed Web of Science ®Google Scholar
• Galindo M, Pratap J, Young DW et al. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J. Biol. Chem.280, 20274–20285 (2005).
   PubMed Web of Science ®Google Scholar
• Gaur T, Lengner CJ, Hovhannisyan H et al. Canonical WNT signaling promotes osteogenesis by directly stimulating runx2 gene expression. J. Biol. Chem.280, 33132–33140 (2005).
   PubMed Web of Science ®Google Scholar
• Oyama M, Kozuka-Hata H, Suzuki Y, Semba K, Yamamoto T, Sugano S. Diversity of translation start sites may define increased complexity of the human short ORFeome. Mol. Cell. Proteomics6, 1000–1006 (2007).
   PubMed Web of Science ®Google Scholar
• Jimenez CR, Spijker S, de Schipper S et al. Peptidomics of a single identified neuron reveals diversity of multiple neuropeptides with convergent actions on cellular excitability. J. Neurosci.26, 518–529 (2006).
   PubMedGoogle Scholar
• Helmerhorst EJ, Oppenheim FG. Saliva: a dynamic proteome J. Dent. Res.86, 680–693 (2007).
   PubMed Web of Science ®Google Scholar
• Kiernan UA. Quantification of target proteins and post-translational modifications in affinity-based proteomic approaches. Expert Rev. Proteomics4(3), 421–428 (2007).
   PubMed Web of Science ®Google Scholar
• Xiao GG, Recker RR, Deng HW. Recent advances in proteomics and cancer biomarker discovery. Clin. Med. Oncol.2, 1–10 (2008).
   PubMedGoogle Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature422, 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lee WN, Xiao GG. Quantitative proteomics and biomarker discovery in human cancer. Expert Rev. Proteomics6(2), 115–118 (2009).
   PubMed Web of Science ®Google Scholar
• Kubota K, Wakabayashi K, Matsuoka T. Proteome analysis of secreted proteins during osteoclast differentiation using two different methods: two-dimensional electrophoresis and isotope-coded affinity tags analysis with two-dimensional chromatography. Proteomics3, 616–626 (2003).
   PubMedGoogle Scholar
• Wilson R, Belluoccio D, Little CB, Fosang AJ, Bateman JF. Proteomic characterization of mouse cartilage degradation in vitro. Arthritis Rheum.58, 3120–3131 (2008).
   PubMed Web of Science ®Google Scholar
• Kawai A, Kondo T, Suehara Y, Kikuta K, Hirohashi S. Global protein-expression analysis of bone and soft tissue sarcomas. Clin. Orthop. Relat. Res.466, 2099–2106 (2008).
   PubMed Web of Science ®Google Scholar
• Guo D, Tan W, Wang F et al. Proteomic analysis of human articular cartilage: identification of differentially expressed proteins in knee osteoarthritis. Joint Bone Spine75, 439–444 (2008).
   PubMed Web of Science ®Google Scholar
• Tan X, Cai D, Wu Y et al. Comparative analysis of serum proteomes: discovery of proteins associated with osteonecrosis of the femoral head. Transl. Res.148, 114–119 (2006).
   PubMed Web of Science ®Google Scholar
• Folio C, Mora MI, Zalacain M et al. Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. J. Proteome Res.8(8), 3882–3888 (2009).
   PubMedGoogle Scholar
• Kang JH, Park KK, Lee IS et al. Proteome analysis of responses to ascochlorin in a human osteosarcoma cell line by 2-D gel electrophoresis and MALDI-TOF MS. J. Proteome Res.5, 2620–2631 (2006).
   PubMedGoogle Scholar
• Cubukcuoglu Deniz G, Durdu S, Akar AR, Ozyurda U. Biotechnology and stem cell research: a glance into the future. Anadolu Kardiyol. Derg.8, 297–302 (2008).
   PubMedGoogle Scholar
• Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature418, 41–49 (2002).
   PubMed Web of Science ®Google Scholar
• Hassan HT, El-Sheemy M. Adult bone-marrow stem cells and their potential in medicine. J. R. Soc. Med.97, 465–471 (2004).
   PubMedGoogle Scholar
• Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res. Ther.9, 204 (2007).
   PubMed Web of Science ®Google Scholar
• Celebi B, Elcin YM. Proteome analysis of rat bone marrow mesenchymal stem cell subcultures. J. Proteome Res.8, 2164–2172 (2009).
   PubMed Web of Science ®Google Scholar
• Mareddy S, Broadbent J, Crawford R, Xiao Y. Proteomic profiling of distinct clonal populations of bone marrow mesenchymal stem cells J. Cell. Biochem.106, 776–786 (2009).
   PubMed Web of Science ®Google Scholar
• Foster LJ, Zeemann PA, Li C, Mann M, Jensen ON, Kassem M. Differential expression profiling of membrane proteins by quantitative proteomics in a human mesenchymal stem cell line undergoing osteoblast differentiation. Stem Cells23, 1367–1377 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng X, McDonald JM. The role of calmodulin in the regulation of osteoclastogenesis. Endocrinology144, 4536–4543 (2003).
   PubMedGoogle Scholar
• Sun HJ, Bahk YY, Choi YR et al. A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell. J. Orthop. Res.24, 2059–2071 (2006).
   PubMed Web of Science ®Google Scholar
• Spreafico A, Frediani B, Capperucci C et al. A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics6, 3520–3532 (2006).
   PubMed Web of Science ®Google Scholar
• Kim SH, Jun S, Jang HS, Lim SK. Identification of parathyroid hormone-regulated proteins in mouse bone marrow cells by proteomics. Biochem. Biophys. Res. Commun.330, 423–429 (2005).
   PubMedGoogle Scholar
• Xu J, Khor KA, Sui J, Zhang J, Tan TL, Chen WN. Comparative proteomics profile of osteoblasts cultured on dissimilar hydroxyapatite biomaterials: an iTRAQ-coupled 2-D LC-MS/MS analysis. Proteomics8, 4249–4258 (2008).
   PubMed Web of Science ®Google Scholar
• Bennett KP, Bergeron C, Acar E et al. Proteomics reveals multiple routes to the osteogenic phenotype in mesenchymal stem cells. BMC Genomics8, 380 (2007).
   PubMedGoogle Scholar
• Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science308, 1472–1477 (2005).
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell93, 165–176 (1998).
   PubMed Web of Science ®Google Scholar
• Ha BG, Hong JM, Park JY et al. Proteomic profile of osteoclast membrane proteins: identification of Na+/H+ exchanger domain containing 2 and its role in osteoclast fusion. Proteomics8, 2625–2639 (2008).
   PubMedGoogle Scholar
• Czupalla C, Mansukoski H, Pursche T, Krause E, Hoflack B. Comparative study of protein and mRNA expression during osteoclastogenesis. Proteomics5, 3868–3875 (2005).
   PubMed Web of Science ®Google Scholar
• Kendler DL, Roux C, Benhamou CL et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res. DOI: 10.1359/jbmr.090716 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Kostenuik PJ, Nguyen HQ, McCabe J et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J. Bone Miner. Res.24, 182–195 (2009).
   PubMed Web of Science ®Google Scholar
• Tang Y, Wu X, Lei W et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med.15, 757–765 (2009).
   PubMed Web of Science ®Google Scholar